KR102753602B1 - 경구 면역요법 방법 - Google Patents

경구 면역요법 방법 Download PDF

Info

Publication number
KR102753602B1
KR102753602B1 KR1020207015239A KR20207015239A KR102753602B1 KR 102753602 B1 KR102753602 B1 KR 102753602B1 KR 1020207015239 A KR1020207015239 A KR 1020207015239A KR 20207015239 A KR20207015239 A KR 20207015239A KR 102753602 B1 KR102753602 B1 KR 102753602B1
Authority
KR
South Korea
Prior art keywords
peanut
subject
level
specific ige
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015239A
Other languages
English (en)
Korean (ko)
Other versions
KR20200083526A (ko
Inventor
스티븐 지. 딜리
Original Assignee
에이뮨 테라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이뮨 테라퓨틱스, 인코퍼레이티드 filed Critical 에이뮨 테라퓨틱스, 인코퍼레이티드
Publication of KR20200083526A publication Critical patent/KR20200083526A/ko
Application granted granted Critical
Publication of KR102753602B1 publication Critical patent/KR102753602B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020207015239A 2017-11-02 2018-11-01 경구 면역요법 방법 Active KR102753602B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762580999P 2017-11-02 2017-11-02
US62/580,999 2017-11-02
US201862631406P 2018-02-15 2018-02-15
US62/631,406 2018-02-15
US201862637903P 2018-03-02 2018-03-02
US62/637,903 2018-03-02
US201862674478P 2018-05-21 2018-05-21
US62/674,478 2018-05-21
PCT/US2018/058777 WO2019089978A1 (en) 2017-11-02 2018-11-01 Methods of oral immunotherapy

Publications (2)

Publication Number Publication Date
KR20200083526A KR20200083526A (ko) 2020-07-08
KR102753602B1 true KR102753602B1 (ko) 2025-01-10

Family

ID=66332382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015239A Active KR102753602B1 (ko) 2017-11-02 2018-11-01 경구 면역요법 방법

Country Status (9)

Country Link
US (2) US11369676B2 (https=)
EP (1) EP3703743A4 (https=)
JP (1) JP7498661B2 (https=)
KR (1) KR102753602B1 (https=)
CN (1) CN111344010A (https=)
AU (1) AU2018358125B2 (https=)
CA (1) CA3080601A1 (https=)
MX (1) MX2020004683A (https=)
WO (1) WO2019089978A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP4545077A1 (en) 2017-12-06 2025-04-30 Prollergy Corporation Composition and method for reducing allergic response
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
WO2020100024A1 (en) * 2018-11-12 2020-05-22 Murdoch Childrens Research Institute Method and system
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
EP3965815A4 (en) * 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
CA3162040A1 (en) * 2019-12-23 2021-07-01 Bronwyn POLLOCK Pharmaceutical compositions
AU2020412960A1 (en) * 2019-12-23 2022-06-16 Prota Therapeutics Pty Ltd Allergy treatment
BR112022026945A2 (pt) 2020-07-01 2023-03-07 Nestle Sa Determinação de equipe médica para imunoterapia oral
WO2022089595A1 (en) * 2020-10-30 2022-05-05 Oneness Biotech Co., Ltd. Biomarkers for ige-mediated diseases
JP2024509087A (ja) * 2021-02-24 2024-02-29 オールアダプト イミュノセラピューティクス，インコーポレイテッド アレルギーの治療方法
US20250342925A1 (en) * 2022-04-15 2025-11-06 Samsung Life Public Welfare Foundation Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy
WO2014159609A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
DE102011086048A1 (de) 2011-04-07 2012-10-11 Continental Teves Ag & Co. Ohg Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
EP3568027A4 (en) 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20140093541A1 (en) * 2011-03-17 2014-04-03 Cambridge University Hospitals Nhs Foundation Treatment for peanut allergy
WO2014159609A1 (en) * 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Michaud et al. Trials, 16(197)(2015)*

Also Published As

Publication number Publication date
AU2018358125A1 (en) 2020-05-14
US20190167785A1 (en) 2019-06-06
CA3080601A1 (en) 2019-05-09
MX2020004683A (es) 2020-08-13
JP7498661B2 (ja) 2024-06-12
US11369676B2 (en) 2022-06-28
EP3703743A4 (en) 2021-12-08
CN111344010A (zh) 2020-06-26
EP3703743A1 (en) 2020-09-09
US12357688B2 (en) 2025-07-15
AU2018358125B2 (en) 2025-09-04
WO2019089978A1 (en) 2019-05-09
JP2021501763A (ja) 2021-01-21
KR20200083526A (ko) 2020-07-08
US20220288196A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
KR102753602B1 (ko) 경구 면역요법 방법
US12016917B2 (en) Peanut formulations and uses thereof
Vickery et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective
AU2012228033B2 (en) Treatment for peanut allergy
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Reinwald et al. Peanut oral immunotherapy: current trends in clinical trials
Yahia et al. Oral immunotherapy for children with a high-threshold peanut allergy
Porcaro et al. Anaphylaxis to cutaneous exposure to bovine colostrum based cream
Pignatti et al. Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: basophil reactivity to excipients
US20250179216A1 (en) ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
US20250011474A1 (en) ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
WO2025010086A1 (en) Anti-ige antibody therapy for multiple food allergies
Kattan Oral food challenges in routine clinical practice
Cosper et al. 7 to 11: Food Allergy Treatment Therapies
Li Immunological Humoral and Cellular Activation Profiles in the Low Dose Multi Allergen Oral Immunotherapy Trial
Reinwald et al. Corresponding author: Menno C. van Zelm, PhD
O'Hehir Peanut oral immunotherapy: current trends in clinical trials
SIMPSON et al. British Society for Allergy and Clinical Immunology 18th–20th July 2005
HK1194000A (en) Treatment for peanut allergy
HK1194000B (en) Treatment for peanut allergy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241127

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250108

End annual number: 3

Start annual number: 1

PG1601 Publication of registration